Fibrinogen and pentoxifylline

Bachet, P.; Lancrenon, S.; Chassoux, G

doi:10.1016/0049-3848(89)90466-0

Cited by 9 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 The mode of action of the methlyxanthine derivatives is not fully understood, and the mechanism remains unknown. [9][10] The PTX inhibits several cytokines, such as interleukines and tumor necrosis factor-alpha (TNF-a). 9 There are studies in rats and humans (in vivo and in vitro) describing the inhibition of cytokines by PTX, [11][12][13][14][15] and PTX and other methylxanthine derivatives seem to suppress TNF-a synthesis.…”

mentioning

confidence: 99%

“…28 By inhibiting the synthesis of TNF-a by activated monocytes, PTX can probably decrease fibrinogen levels, a common component of the effusion in cats with FIP. 10,19 It was previously postulated that high fibrinogen levels could be an index of TNF-a levels. This finding is supported by a close correlation between decreased fibrinogen levels and clinical improvement.…”

mentioning

confidence: 99%

“…In these reports it has been suggested that PTX is likely to decrease vasculitis, which is responsible for the majority of clinicopathological findings of FIP . The mode of action of the methlyxanthine derivatives is not fully understood, and the mechanism remains unknown . The PTX inhibits several cytokines, such as interleukines and tumor necrosis factor‐alpha (TNF‐α) .…”

mentioning

confidence: 99%

“…TNF‐α also induces fibrinogen synthesis, and is responsible for an increased production of free radicals which cause endothelial cell damage . By inhibiting the synthesis of TNF‐α by activated monocytes, PTX can probably decrease fibrinogen levels, a common component of the effusion in cats with FIP . It was previously postulated that high fibrinogen levels could be an index of TNF‐α levels.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Randomized, Placebo Controlled Study of the Effect of Propentofylline on Survival Time and Quality of Life of Cats with Feline Infectious Peritonitis

Fischer¹,

Ritz²,

Weber³

et al. 2011

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Currently there is no drug proven to effectively treat cats with feline infectious peritonitis (FIP). Hypothesis: Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.Animals: Twenty-three privately owned cats with FIP. Methods: Placebo-controlled double-blind trial. FIP was confirmed by histology or immunostaining of feline coronavirus (FCoV) antigen in effusion or tissue macrophages or both. The cats were randomly selected for treatment with either PPF or placebo. All cats received additional treatment with glucocorticoids, antibiotics, and low molecular weight heparin according to methods.Results: There was no statistically significant difference in the survival time of cats treated with PPF (8 days, 95% CI 5.4-10.6) versus placebo (7.5 days, 95% CI 4.4-9.6). The median survival time of all cats was 8 days (4-36 days). There was neither a difference in quality of life (day 7, P = .892), in the amount of effusion (day 7, P = .710), the tumor necrosis factor-alpha (TNF-a) concentration (day 7, P = .355), nor in any other variable investigated in this study, including a complete blood count, and a small animal biochemistry profile.Conclusions and Clinical Importance: This study did not detect an effect of PPF on the survival time, the quality of life, or any clinical or laboratory parameter in cats with FIP. Therefore, PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.

show abstract